Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2

Kuan Der Lee, Hsin Wei Chen, Chih G. Chen, Yan Chung Shih, Hsing Kun Liu, Mei Lien Cheng

研究成果: 雜誌貢獻文章同行評審

1 引文 斯高帕斯(Scopus)

摘要

T cells can be activated in vitro by monoclonal antibodies to CD3 (anti-CD3) to become non-MHC restricted killer cells (CD3-AK). Anti-CD3 activation upregulates the expression of the interleukin (IL)-2 receptors on T cells whose expansion is facilitated by IL-2. The therapeutic effect of in vivo administration of anti-CD3 and IL-2 has been investigated in many types of human cancers. To circumvent the toxicities posed by systemic administration of high-dose IL-2, there is interest in forming a strategy for targeting and concentrating IL-2 at the site where it is needed. This study investigates the feasibility of constructing a novel fusion protein consisting of IL-2 fused to the constant region of anti-CD3 antibody. Our results indicate that the specific IL-2 receptor-binding capability and bioactivity of the IL-2 portion as well as the CD3-binding and biological functions of anti-CD3 portion remain intact in this anti-CD3/IL-2 fusion protein. Thus, cytokines fused to anti-CD3 antibody by genetic engineering is feasible and may provide a new class of immunotherapeutics for cancer.
原文英語
頁(從 - 到)1211-1216
頁數6
期刊Oncology Reports
15
發行號5
出版狀態已發佈 - 五月 2006
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2」主題。共同形成了獨特的指紋。

引用此